Insightful analysis and commentary for the US and global equity investor
Contributors: Douglas McIntyre Jon C. Ogg

Previous Posts

Monday, July 31, 2006

Plavix Settlement Fallout

Stock Tickers: BMY, SNY, CEPH

Bristol-Myers Squibb (BMY) is down 1.8% pre-market at $24.01 after the state attorneys general rejected their pact with Apotex over generic Plavix. This was formalized on Friday afternoon, but had been telegraphed before this after the earnings because of the DOJ/FTC issues. This of course means that Sanofi-Aventis (SNY) was left in the lurch as well.

What is interesting is that Cephalon (CEPH) is trading lower in sympathy, but even worse in terms of percentages. CEPH stock was down as much as almost $5.50 pre-market, but is now trading down $3.73 at $62.31 in pre-market trading. This company is merelt deemed as a potential patent "at risk" situation because of its patent agreements with generic companies over its Provigil, which "could" face the same scrutiny at some point. While this seems extreme, that is the way the ball bounces sometimes.

Jon C. Ogg
July 31, 2006

Powered by Blogger